Clonal evolution in myeloma: a narrow road to remission

Over the last twenty years, a wave of new therapies has made a profound impact on the treatment and prognosis of multiple myeloma. The advent of proteasome inhibitors and thalidomide and its successors have increased the response rates to first-line therapy in myeloma to more than 90%, with a median